Zynerba Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer

DEVON, Pa., Sept. 13, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company’s Board of Directors granted James Fickenscher, the Company’s newly appointed Chief Financial Officer and Vice President, Corporate Development, an option to purchase 150,000 shares of the Company’s common stock as an inducement material to his acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).  The option will have an exercise price equal to the closing price of Zynerba Pharmaceuticals’ common stock on September 13, 2016.  The option will vest 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to Mr. Fickenscher’s continued service with the Company through the applicable vesting dates.

Click here to read the full press release.

©2020 PACT All Rights Reserved